Just a moment, the page is loading...

Prediction of efficacy and tolerability of antidepressants and mood stabilizers

Prediction of efficacy and tolerability of antidepressants and mood stabilizers

Lasse Brandt

Department of Psychiatry and Psychotherapy, Charité Campus Mitte, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

11 January 2023

Antidepressants and mood stabilizers are drugs for the treatment of psychiatric disorders such as depression and bipolar disorder. Psychiatrists aim to recommend an optimal drug depending on the individual symptoms and risk of adverse events. The drug would ideally improve the symptoms with a low risk of adverse events.Individualized prediction of the response to a drug and the occurrence of adverse events could improve psychiatric treatment but the identification of predictors is not well-established and remains a challenge. Machine learning techniques are statistical models that could help to identify these predictors. We aim to identify predictors, which are associated with a better treatment response and lower risk of adverse events. To this end, we will assess predictors in a comprehensive dataset of drug trials of antidepressants and mood stabilizers in affective disorders with machine learning techniques.

[{ "PostingID": 53, "Title": "GSK-LBI108884", "Description": "An Open-Label Trial Measuring Satisfaction and Convenience of Two Formulations of Lamotrigine in Subjects with a Mood Disorder" },{ "PostingID": 55, "Title": "GSK-SCA104779", "Description": "Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients" },{ "PostingID": 56, "Title": "GSK-SCA106052", "Description": "Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407))" },{ "PostingID": 82, "Title": "GSK-PIR112487", "Description": "A randomised, double-blind, placebo controlled, parallel group , flexible dose study to evaluate the efficacy and safety of Paxil® Tablets in children and adolescents with Major Depressive Disorder

Statistical Analysis Plan